Arcutis Biotherapeutics
ARQT
186 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.
158% more call options, than puts
Call options by funds: $7.03M | Put options by funds: $2.73M
62% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 29
11% more funds holding
Funds holding: 168 → 186 (+18)
7% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 55
0.57% more ownership
Funds ownership: 108.71% → 109.28% (+0.57%)
5% less capital invested
Capital invested by funds: $1.24B → $1.18B (-$61.9M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$20.9M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$19.2M |
| 3 |
BlackRock
New York
|
+$17.8M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$11.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$33M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$15.9M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$12.9M |
| 4 |
SC
Stempoint Capital
New York
|
-$11.2M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$8.87M |
ARQT Hedge Fund Activity: Q2 2024 in Review
186 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2024, worth a combined $1.18B — down 5% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ARQT positions and 29 closed out — a net gain of 18 holders — while 59 added to existing stakes and 55 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $20.9M. The largest seller was State Street, cutting an estimated $33M.
- 186 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2024, up from 168 in Q1 2024.
- Funds reported $1.18B of Arcutis Biotherapeutics stock for Q2 2024, down 5% quarter-over-quarter.
- 47 funds opened new Arcutis Biotherapeutics positions in Q2 2024 and 29 closed out, a net change of +18 holders.
- The largest Arcutis Biotherapeutics buyer in Q2 2024 was Rubric Capital Management (New York), an estimated $20.9M added.
- The largest Arcutis Biotherapeutics seller in Q2 2024 was State Street, an estimated $33M sold.
Based on aggregated 13F filings for Q2 2024.